文献速递肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

简化腹膜后机器人单孔手术:新型仰卧位前腹膜后入路

Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access.
PubMed 文献 · Eur Urol · 2023-05-19

本研究评估仰卧位前腹膜后入路(SARA)联合达芬奇单孔(SP)机器人平台治疗肾癌、尿路上皮癌或输尿管狭窄的可行性与安全性。2022年10月至2023年1月共18例患者接受手术,其中12例行肾部分切除术。结果显示该入路可行且安全,但需更大规模研究证实。

要点

  • SARA技术联合达芬奇SP平台在18例上尿路手术中可行且安全。
  • 肾部分切除术组中位热缺血时间25分钟,中位手术时间160分钟。
  • 肾部分切除术组83%患者手术当日出院,术后7天无患者报告使用麻醉性镇痛药。

核心结论

  • SARA入路可行且安全,需更大规模研究证实其作为上尿路手术一站式解决方案的地位。

研究设计与样本

  • 前瞻性收集2022年10月至2023年1月共18例接受SARA技术手术患者的围手术期变量并评估结局。

主要发现

  • 18例中12例行肾部分切除术,2例行肾盂成形术,2例行根治性肾输尿管切除术,2例行根治性肾切除术。
  • 肾部分切除术组平均年龄57岁(四分位距30-73),中位体重指数32 kg/m2(四分位距17-58),25%患有≥3期慢性肾病。
  • 肾部分切除术组中位Charlson合并症指数为3(四分位距0-7),75%患者美国麻醉医师协会评分≥3。
  • 肾部分切除术组中位RENAL评分为5(四分位距4-7),中位热缺血时间25分钟(四分位距16-48),中位肿瘤大小35 mm(四分位距16-50)。
  • 肾部分切除术组中位估计失血量105 ml(四分位距20-400),中位手术时间160分钟(四分位距110-200),1例患者手术切缘阳性。

关键数值与推荐

  • 总体队列中1例患者再入院并接受保守治疗。
  • 肾部分切除术组83%患者手术当日出院,其余患者次日出院。
  • 术后7天无患者报告使用麻醉性镇痛药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模的研究来证实该入路作为上尿路手术一站式解决方案的地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiport robotic surgery in the retroperitoneum is limited by the bulky robotic frame and clashing of instruments. Moreover, patients are placed in the lateral decubitus position, which has been linked to complications. OBJECTIVE: To assess the feasibility and safety of a supine anterior retroperitoneal access (SARA) technique with the da Vinci Single-Port (SP) robotic platform. DESIGN, SETTING, AND PARTICIPANTS: Between October 2022 and January 2023, 18 patients underwent surgery using the SARA technique for renal cancer, urothelial cancer, or ureteral stenosis. Perioperative variables were prospectively collected and outcomes were assessed. SURGICAL PROCEDURE: With the patient in a supine position, a 3-cm incision is made at the McBurney point and the abdominal muscles are dissected. Finger dissection is used to develop the retroperitoneal space for the da Vinci SP access port. After docking, the first step is to dissect retroperitoneal tissue to reveal the psoas muscle. This allows identification of the ureter, the inferior renal pole, and the hilum. MEASUREMENTS: A descriptive statistical analysis was performed. Data collected included demographics, operative time, warm ischemia time (WIT), surgical margin status, complications, length of hospital stay, 30-d Clavien-Dindo complications, and postoperative narcotic use. RESULTS AND LIMITATIONS: Twelve patients underwent partial nephrectomy (PN) and two each underwent pyeloplasty, radical nephroureterectomy, and radical nephrectomy. In the PN group, mean age was 57 yr (interquartile range [IQR] 30-73), median body mass index was 32 kg/m2 (IQR 17-58), and 25% had stage ≥3 chronic kidney disease. The median Charlson comorbidity index was 3 (IQR 0-7) and 75% of PN patients had an American Society of Anesthesiologists score ≥3. The median RENAL score was 5 (IQR 4-7). The median WIT was 25 min (IQR 16-48) and the median tumor size was 35 mm (IQR 16-50). The median estimated blood loss was 105 ml (IQR 20-400) and the median operative time was 160 min (IQR 110-200). Positive surgical margins were found in one patient. In the overall cohort, one patient was readmitted and managed conservatively; 83% of the PN group were discharged on the same day as their surgery, with the remainder discharged the next day. At 7 d after surgery, no patients reported narcotic use. CONCLUSIONS: The SARA approach is feasible and safe. Larger studies are needed to confirm this approach as a one-step solution for upper urinary tract surgery. PATIENT SUMMARY: We assessed initial outcomes of a novel approach for accessing the retroperitoneum (the space behind the abdominal cavity and in front of the back muscles and spine) during robot-assisted surgery in the upper urinary tract. The patient is placed on their back and surgery is performed with a single-port robot. Our results show that this approach was feasible and safe, with low complication rates, less postoperative pain, and earlier discharge. This is a promising start, but larger studies are needed to confirm our findings.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pellegrino AA, Chen G, Morgantini L, et al. Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access. Eur Urol. 2023. PMID: 37211448. doi:10.1016/j.eururo.2023.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。